Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program

Executive Summary

• Telo Genomics announced the launch of a retrospective multiple myeloma Minimal Residual Disease (MRD) clinical trial in partnership with the University of Athens.
• The study will evaluate the prognostic performance of Telo’s blood‑based TeloView® MRD assay against established Next‑Generation Flow (NGF) MRD results, using well‑characterized samples with ~3 years of follow‑up.
• Successful validation could support broader adoption of TeloView® MRD and strengthen the company’s multi‑center evidence package ahead of anticipated Q1 2026 announcements.

Key Details

• Collaboration Partner: National and Kapodistrian University of Athens, led by Prof. Meletios A. Dimopoulos and Prof. Efstathios Kastritis.
• Study Design: Retrospective analysis of archived clinical blood samples with known patient outcomes; includes serial NGF MRD results from both blood and bone marrow.
• Assay Sensitivity: TeloView® MRD claims a limit of detection down to 1 in 10⁷ cells (one myeloma cell among ten million blood cells), compared with NGF’s typical 10⁶ sensitivity.
• Comparative Goal: Assess how well TeloView® MRD predicts relapse risk versus NGF, and determine any incremental prognostic value from 3‑D genomic architecture analysis of MRD cells.
• Cohort Characteristics: Samples have an average follow‑up period of approximately three years, providing robust outcome data for validation.
• Future Plans: Telo continues prospective MRD trials with Cleveland Clinic and Jewish General Hospital; expects to announce additional retrospective collaborations in Q1 2026.
• Strategic Impact: Validation could position TeloView® MRD as a less invasive, high‑sensitivity alternative to bone‑marrow–based NGF/NGS assays, expanding the addressable market (estimated >750,000 MM tests/year in the U.S.).

Notable Quotes

• “We are pleased to be working with Prof. Meletios A. Dimopoulos and Prof. Efstathios Kastritis from the National and Kapodistrian University of Athens,” said Dr. Sabine Mai, Co‑Founder of Telo Genomics. “This collaboration is expected to meaningfully strengthen our mission to help redefine MRD‑guided clinical practice by bringing more actionable, blood‑based insights to physicians and patients.”